<DOC>
	<DOCNO>NCT01081834</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety , tolerability 2 different dos canagliflozin administer monotherapy compare placebo patient type 2 diabetes mellitus ( T2DM ) inadequately control diet exercise .</brief_summary>
	<brief_title>The CANTATA-M ( CANagliflozin Treatment Trial Analysis - Monotherapy ) Trial</brief_title>
	<detailed_description>Canagliflozin drug test see may useful treat patient diagnose type 2 diabetes mellitus ( T2DM ) . This randomize ( study drug assign chance ) , double blind ( neither patient study doctor know name assign treatment ) , parallel-group , 3 arm ( patient assign 1 3 treatment group ) multicenter study determine efficacy , safety , tolerability canagliflozin ( 100 mg 300 mg ) compare placebo ( capsule look like treatment real medicine ) patient diagnose T2DM achieve adequate response diet exercise control diabetes . Approximately 450 patient inadequate glycemic control diet exercise receive once-daily treatment canagliflozin 100 mg 300 mg daily 52 week 26 week double-blind treatment placebo follow 26 week sitagliptin 100 mg ( sitagliptin antihyperglycemic agent allow patient randomized placebo group improve glycemic control remain study ) . Patients participate study approximately 60 68 week ( refer Main Study ) . The study also include High Glycemic Substudy 50 100 patient T2DM poor glycemic control diet exercise . Patients substudy assign receive double-blind canagliflozin 100 mg 300 mg 26 week total duration patient participatation substudy approximately 34 42 week . During treatment , patient 's fasting blood sugar remain high despite treatment study drug reinforcement diet exercise , patient receive treatment metformin ( rescue therapy ) consistent local prescribe information . Study drug take orally ( mouth ) daily first meal day unless otherwise specify . Patients take single blind placebo 1 2 week ( wks ) randomization Main Study High Glycemic Substudy .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Canagliflozin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>All patient must diagnosis T2DM Patients main study must Hemoglobin A1c ( HbA1c ) &gt; =7 % &lt; =10 % fast plasma glucose ( FPG ) &lt; 270 mg/dL ( 15 mmol/L ) Patients High Glycemic Cohort Substudy must HbA1c &gt; 10 % &lt; =12 % FPG &lt; =350 mg/dL ( 19.44 mmol/L ) History diabetic ketoacidosis , type 1 diabetes mellitus ( T1DM ) , pancreas beta cell transplantation , diabetes secondary pancreatitis pancreatectomy , severe hypoglycemic episode within 6 month screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Diabetes Mellitus , Type 2</keyword>
	<keyword>Canagliflozin</keyword>
	<keyword>Placebo</keyword>
	<keyword>Hemoglobin A1c</keyword>
	<keyword>Type 2 diabetes mellitus</keyword>
</DOC>